Previous 10 | Next 10 |
SAN DIEGO, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it has entered in...
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that it has entered in...
SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (“Arcturus” or the “Company”), a leading RNA medicines company, today announced that the Cystic Fibrosis Foundation (CF Foundation), has increased its commitment to $15 million in conjunction with...
Gainers: IRadimed Corporation (NASDAQ: IRMD ) +28% . AirNet Technology (NASDAQ: ANTE ) +28% . LSB Industries (NYSE: LXU ) +22% . CNX Resources Corporation (NYSE: CNX ) +20% . Trex Company (NYSE: TREX ) +19% . ReTo Eco-Solutions (NASDAQ: RETO ) +17% . Medpace Holdings (NASDAQ: M...
SAN DIEGO, Calif., July 10, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics (NASDAQ: ARCT) (the “Company”), a leading messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases, today announced that Joseph Payne...
Shares of Ultragenyx Pharmaceutical ( RARE ) have risen by 37% since my January update recommended readers establish a pilot position and accumulate dips in the near term as a turnaround appeared likely. Now that the stock has pulled back from highs last seen in April, I'm looking forward ...
Mirth is like a flash of lightning that breaks through a gloom of clouds and glitters for a moment. ” ― Joseph Addison Today, we look at a small RNA developmental concern whose stock has had a nice run over the past few weeks. Can the rally continue? We take an in-depth inve...
Mirth is like a flash of lightning that breaks through a gloom of clouds and glitters for a moment. ” ― Joseph Addison Today, we look at a small RNA developmental concern whose stock has had a nice run over the past few weeks. Can the rally continue? We take an in-depth inve...
The FDA designates Arcturus Therapeutics' (NASDAQ: ARCT ) lead candidate ARCT-810 an Orphan Drug for the treatment of ornithine transcarbamylase deficiency (OTCD), a relatively rare urea cycle disorder in which ammonia accumulates in the body leading to nervous system damage. More news...
SAN DIEGO, June 27, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, liver and respiratory diseases with significant unmet medical need, today announced...
News, Short Squeeze, Breakout and More Instantly...
Arcturus Therapeutics Ltd. Company Name:
ARCT Stock Symbol:
NASDAQ Market:
Arcturus Therapeutics Ltd. Website:
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and medicines to treat unmet medical needs within liver and respiratory rare diseases, toda...
2024-07-02 10:15:03 ET Piper Sandler analyst issues OVERWEIGHT recommendation for ARCT on July 2, 2024 08:19AM ET. The previous analyst recommendation was Overweight. ARCT was trading at $23.66 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
ARCT-810 Phase 2 study completed enrollment at 0.3 mg/kg dose level in Europe with data expected later this year ARCT-810 to expand Phase 2 clinical program in the U.S. to enroll patients with more severe disease ARCT-032 IND for Phase 2 multiple ascending dose study to be submitt...